METIS TECHBIO-P's stock plummeted 5.50% during intraday trading on Thursday, extending a sustained retreat since its market debut earlier this month.

The decline reflects ongoing profit-taking pressure and rapidly cooling post-IPO market enthusiasm. Despite recently announcing a strategic alliance with healthcare investment firm Deerfield Management to advance AI-driven protein therapeutics, the stock has faced selling pressure as some international placement shares were not subject to lock-up restrictions.

As the world's first AI-driven drug delivery company to list on the Hong Kong Stock Exchange, METIS TECHBIO-P remains in early-stage commercialization with approximately RMB 1.5 billion in accumulated losses over the past three years and volatile revenue. The market's initial exuberance following its 173% surge from the IPO price on debut has continued to fade, sustaining downward pressure on the share price.